Genentech Sues Pfizer Over Herceptin Biosimilar Patents

Drug Industry Daily
A A
Genentech filed a lawsuit aiming to stop Pfizer’s proposed Herceptin biosimilar from reaching the market — asking the court to compensate for losses in sales should the copy launch before 2019, when several patents are set to expire.

To View This Article:

Login

Subscribe To Drug Industry Daily